FDA Expands Approvals of Ferriprox

FDA Expands Approvals of Ferriprox

293553

FDA Expands Approvals of Ferriprox

The U.S. Food and Drug Administration (FDA) has expanded the label of Chiesi Global Rare Diseases’ iron-binding oral treatment Ferriprox (deferiprone) to include patients ages 3 and older who have blood transfusion-induced iron overload due to sickle cell disease (SCD) or other anemias. The therapy was first approved in 2011 for transfusional iron overload in people with thalassemia, another inherited blood disorder, when current iron-binding, or iron-chelating, treatment was ineffective. Ferriprox oral tablets are indicated…

You must be logged in to read/download the full post.